2026年11月2日星期一
M
Panorama Universal
Notícias globais
Nuclear reactors under construction rise to 79 globally on AI demand— 日经 Nikkei AsiaAI dubbing to help Japanese companies expand global outreach— 日经 Nikkei AsiaIndonesia GDP, US midterm elections, Hong Kong financial summit— 日经 Nikkei AsiaPakistan refineries report 1,860% jump in profit amid war windfall— 日经 Nikkei AsiaAfter US midterms, democracy will face test of ability to self-correct— 日经 Nikkei AsiaThai reformists became too technocratic, party ex-leader Pita says— 日经 Nikkei AsiaJapan bamboo chopsticks catch on in South Korea— 日经 Nikkei AsiaOn India's east coast, tidepooling inspires marine conservation— 日经 Nikkei AsiaNuclear reactors under construction rise to 79 globally on AI demand— 日经 Nikkei AsiaAI dubbing to help Japanese companies expand global outreach— 日经 Nikkei AsiaIndonesia GDP, US midterm elections, Hong Kong financial summit— 日经 Nikkei AsiaPakistan refineries report 1,860% jump in profit amid war windfall— 日经 Nikkei AsiaAfter US midterms, democracy will face test of ability to self-correct— 日经 Nikkei AsiaThai reformists became too technocratic, party ex-leader Pita says— 日经 Nikkei AsiaJapan bamboo chopsticks catch on in South Korea— 日经 Nikkei AsiaOn India's east coast, tidepooling inspires marine conservation— 日经 Nikkei Asia

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

Fonte Nature 医学研究Há 4 dias
Resumo do conteúdo

Este site fornece apenas o título e o índice do resumo; o conteúdo completo e os direitos autorais pertencem ao publicador original. Clique no link do texto original para ler.

Ir para o texto original
Canal de origem
Saúde
Região de origem
Perspetiva global
Idioma do texto original
English
Número do item
health-a97f47b5

Comments 0 comments

No comments yet. Be the first.

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial · Panorama Universal